The drug, known as ICA-17043, is part of new class of drugs known as Gardos channel
The drug, known as ICA-17043, is part of new class known as Gardos channel
Abstract #685 - A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel
Blocker, in Patients with Sickle Cell Disease
ICA-17043 targets a particular potassium channel, called the Gardos channel
, that is located on the membrane of red blood cells.
It is our present intent, subject to further input from the DMC, to complete the modified ASSERT trial as we seek to establish the benefit of this novel Gardos channel
inhibitor, when used in combination with hydroxyurea, to reduce the rate of vaso-occlusive crises in patients with sickle cell disease.
We look forward to the completion of enrollment in this pivotal Phase III trial studying the effect of ICA-17043, a novel Gardos channel
inhibitor, on the rate of vaso-occlusive crisis in patients with sickle cell disease.
Supporting the findings of our Phase II study, these results suggest that block of the Gardos channel
with ICA-17043 results in a sustained reduction in hemolysis and improvement in anemia in patients with sickle cell anemia.